Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience

Pseudomonas aeruginosa is a leading cause of nosocomial infections, which are often severe [1, 2] and difficult to treat because of their increasing resistance to several antibiotics, including carbapenems [3-6]. For such infections, there are limited therapeutic options, and old antibiotics such as colistin, aminoglycosides or fosfomycin are frequently prescribed [7]. Clinical failure [8], emergence of in vivo resistance [9], superinfection, and nephrotoxicity [10, 11] represent the main limitations of the currently available drugs, leading to the search of new treatment options.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research